Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?

The global spread of carbapenem-resistant Enterobacteriaceae (CRE) is increasingly becoming a major challenge in clinical and public health settings. To date, the treatment for serious CRE infections remains difficult. The intelligent use of antimicrobials and effective infection control strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Michele, Pop-Vicas, Aurora E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075344/
https://www.ncbi.nlm.nih.gov/pubmed/25041592
http://dx.doi.org/10.1186/cc13949
_version_ 1782323326280007680
author Yamamoto, Michele
Pop-Vicas, Aurora E
author_facet Yamamoto, Michele
Pop-Vicas, Aurora E
author_sort Yamamoto, Michele
collection PubMed
description The global spread of carbapenem-resistant Enterobacteriaceae (CRE) is increasingly becoming a major challenge in clinical and public health settings. To date, the treatment for serious CRE infections remains difficult. The intelligent use of antimicrobials and effective infection control strategies is crucial to prevent further CRE spread. Early consultation with experts in the treatment of infections with multidrug-resistant organisms is valuable in patient management. This brief review will focus on the current, yet limited, treatment options for CRE infections.
format Online
Article
Text
id pubmed-4075344
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40753442015-06-27 Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Yamamoto, Michele Pop-Vicas, Aurora E Crit Care Review The global spread of carbapenem-resistant Enterobacteriaceae (CRE) is increasingly becoming a major challenge in clinical and public health settings. To date, the treatment for serious CRE infections remains difficult. The intelligent use of antimicrobials and effective infection control strategies is crucial to prevent further CRE spread. Early consultation with experts in the treatment of infections with multidrug-resistant organisms is valuable in patient management. This brief review will focus on the current, yet limited, treatment options for CRE infections. BioMed Central 2014 2014-06-27 /pmc/articles/PMC4075344/ /pubmed/25041592 http://dx.doi.org/10.1186/cc13949 Text en Copyright © 2014 Yamamoto and Pop-Vicas; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Yamamoto, Michele
Pop-Vicas, Aurora E
Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
title Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
title_full Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
title_fullStr Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
title_full_unstemmed Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
title_short Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
title_sort treatment for infections with carbapenem-resistant enterobacteriaceae: what options do we still have?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075344/
https://www.ncbi.nlm.nih.gov/pubmed/25041592
http://dx.doi.org/10.1186/cc13949
work_keys_str_mv AT yamamotomichele treatmentforinfectionswithcarbapenemresistantenterobacteriaceaewhatoptionsdowestillhave
AT popvicasaurorae treatmentforinfectionswithcarbapenemresistantenterobacteriaceaewhatoptionsdowestillhave

Ejemplares similares